Diethylstilbestrol

This is a type of hormone medicine. It's used to help manage symptoms related to menopause, like hot flashes. It's not used for worms or infections.

Brand names:Distilbène, Stilbestrol
Medication

What people taking Diethylstilbestrol report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Diethylstilbestrol

What It's For

Diethylstilbestrol (DES) is a man-made (synthetic) form of the hormone estrogen. From 1940 to 1971 it was prescribed to pregnant women in the hope of preventing miscarriage, premature labor and other pregnancy complications. Studies later showed it did not prevent these problems, and in 1971 it was linked to a rare cancer in daughters who had been exposed before birth. The US Food and Drug Administration (FDA) then told doctors to stop prescribing it during pregnancy. DES was also used for a time to treat menopause symptoms, to stop breast milk production after childbirth, as emergency contraception and to treat advanced prostate cancer. Today no FDA-approved DES product is sold in the United States: every former product, including the brands Stilbetin and Stilphostrol, is listed as discontinued. Its one remaining medical use is a low dose for some men with castration-resistant prostate cancer, meaning prostate cancer that keeps growing despite standard testosterone-lowering treatment. In the US it is rarely used for this and is generally available only from compounding pharmacies, which prepare medicines individually. Most people who look up DES are not considering taking it. They want to understand what it means that they, or their mother, were exposed to it decades ago.

How It Works

Estrogen acts on cells by attaching to estrogen receptors, proteins that switch on growth and development in tissues such as the uterus, vagina and breast. DES is not built like the body's own estrogen, but it attaches to the same receptors and acts as a powerful estrogen. In prostate cancer, that estrogen signal reaches the brain's hormone control centers (the hypothalamus and pituitary gland), which respond by sending out less luteinizing hormone, the signal that tells the testicles to make testosterone. Lower testosterone deprives the cancer of a hormone it uses to grow. Laboratory studies suggest DES may also act on prostate cancer cells directly, which may help explain why it can still work after other hormone treatments have stopped working. Before birth, the reproductive organs form under carefully timed hormone signals. DES taken during pregnancy crossed into that process and disrupted how the vagina, cervix, uterus and fallopian tubes developed in girls and how the testicles developed in boys. That is why its main harms appeared years later in the children rather than in the mothers. DES is now classed as an endocrine-disrupting chemical and a known cause of cancer in humans.

Dosage & Administration

Because there is no FDA-approved product, there is no current US label with standard dosing. In recent prostate cancer studies, DES was taken by mouth as a tablet, most often 1 mg once a day. Older regimens of 3 to 5 mg a day were largely abandoned after large Veterans Administration studies found that 5 mg daily raised the risk of death from heart and blood vessel disease. Some specialists also prescribe low-dose aspirin to reduce the chance of blood clots, although practice varies. Compounded DES is made by an individual pharmacy rather than by a manufacturer of an approved product, so it is worth confirming the strength and form with both the pharmacy and the prescriber. DES is taken only under the supervision of the specialist managing the cancer, and doses are not changed without that team.

Side Effects

In men treated for prostate cancer, breast enlargement and tenderness (gynecomastia) is the most common side effect and affects most people taking DES. Some clinics give a short course of low-dose radiation to the breasts before or during treatment to prevent it or stop it from progressing. The most serious risk is blood clots and other heart and blood vessel problems. At 1 mg a day, recent studies found clots in fewer than 1 in 10 men, far fewer than with the older, higher doses. Pain, swelling or warmth in one leg should be reported to the care team promptly. Sudden shortness of breath, chest pain, coughing up blood or fainting can mean a clot has traveled to the lungs and needs emergency care right away.

Interactions & Warnings

DES must never be used during pregnancy. Trials showed it did not prevent miscarriage; it actually increased miscarriage and preterm birth, and it caused lasting harm to the exposed children. Like other estrogens taken for menopause symptoms, it also raised the risk of cancer of the uterine lining. For men considering it for prostate cancer, a past blood clot, heart disease or stroke is important to discuss, because DES adds to that risk. The prescriber should know about every other medicine and supplement being taken. The most important warnings now concern people exposed before birth. Daughters of women who took DES, often called DES daughters, have about 40 times the usual risk of clear cell adenocarcinoma, a cancer of the vagina and cervix. It is still rare, affecting about 1 in 1,000 DES daughters, and although the first cases appeared in teenagers and young women, the risk stayed raised into their 40s and 50s. DES daughters are also about twice as likely to develop high-grade precancerous changes in the cervix. Some studies found about twice the usual risk of breast cancer after age 40, but others did not, and the excess may fade with age. One study found about twice the risk of pancreatic cancer, a finding still being studied. Their overall cancer risk is not higher than average. Sons exposed before birth (DES sons) have more testicular abnormalities, such as undescended testicles and small cysts next to the testicle, but no increase in infertility, and no increase in prostate cancer has been shown. Women who took DES while pregnant have a slightly higher risk of breast cancer.

What to Expect

For men treated for prostate cancer, response is tracked with PSA (prostate-specific antigen), a blood test that tends to fall when the cancer is under control. In one study of low-dose DES, about 4 in 10 men treated before chemotherapy saw their PSA fall by half or more, and the cancer was held back for a median of about 30 weeks; some men did not respond at all. Specialists have suggested it as an inexpensive hormone option to try before chemotherapy, but it has not been compared head to head with newer prostate cancer medicines. For people exposed before birth, the effects play out over a lifetime. In a long-running study of thousands of DES daughters, about a third had experienced infertility by age 45, compared with about 1 in 7 unexposed women, and more than half had delivered a baby prematurely, compared with fewer than 1 in 5. Ectopic pregnancy (a pregnancy growing outside the uterus), second-trimester pregnancy loss, stillbirth and menopause before age 45 were also more common. People exposed to DES before birth also have higher rates of high cholesterol, high blood pressure and heart disease. Anyone who knows or suspects they were exposed should tell their health care provider. DES daughters were long advised to have a yearly exam that looked closely at the cervix and vagina; how long that extra checking remains useful as they get older is now uncertain, so it is worth deciding with a clinician. DES daughters and the women who took DES should follow routine breast cancer screening for their age. Many people cannot confirm exposure, because DES was sold under dozens of names and old records are often lost, although a provider may sometimes notice telltale changes during a pelvic exam. Researchers are also studying the grandchildren of women who took DES, and the early findings are tentative.

Questions to Ask Your Doctor

  1. 1.My mother was pregnant with me before the early 1970s; is there any way to find out whether she took DES?
  2. 2.Given my possible DES exposure, which cervical, vaginal and breast checks do you recommend, and for how long?
  3. 3.Should DES exposure change how we approach fertility treatment, pregnancy care or hormone therapy for menopause?
  4. 4.For my prostate cancer, how does low-dose DES compare with the other options at this stage, and what will we do to lower my risk of blood clots?

Last reviewed • Oct 2026

Educational content, not medical advice.